Last updated: 20 June 2022 at 4:16pm EST

Jessica Flechtner Net Worth




The estimated Net Worth of Jessica Baker Flechtner is at least $740 millier dollars as of 2 June 2022. Ms. Flechtner owns over 1,578 units of Genocea Biosciences Inc stock worth over $0 and over the last 11 years he sold GNCA stock worth over $6,781. In addition, he makes $733,544 as Chief Scientific Officer at Genocea Biosciences Inc.

Ms. Flechtner GNCA stock SEC Form 4 insiders trading

Jessica has made over 17 trades of the Genocea Biosciences Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently he sold 1,578 units of GNCA stock worth $95 on 2 June 2022.

The largest trade he's ever made was selling 16,525 units of Genocea Biosciences Inc stock on 25 May 2022 worth over $1,487. On average, Jessica trades about 2,275 units every 94 days since 2014. As of 2 June 2022 he still owns at least 89,027 units of Genocea Biosciences Inc stock.

You can see the complete history of Ms. Flechtner stock trades at the bottom of the page.





Jessica Flechtner biography

Dr. Jessica Baker Flechtner Ph.D. serves as Chief Scientific Officer of the Company. Ms. Jess joined Genocea in 2007, soon after the company was founded, and has held multiple scientific roles since joining Genocea. She has served as our Chief Scientific Officer since February 2016, Senior Vice President of Research from February 2014 to January 2016, Vice President of Research from January 2010 to February 2014, and Senior Director, Research and Development from 2007 to 2010. Prior to joining Genocea, Dr. Flechtner was an Immunology Consultant at BioVest International, Inc. from June 2006 to March 2007, where she guided the development of assays to evaluate the success of the company’s autologous Follicular (Non-Hodgkin’s) Lymphoma vaccine in patients. As a researcher at Mojave Therapeutics, Inc., or Mojave, and Antigenics Inc. (now Agenus), which acquired Mojave’s intellectual property, from 2001 to 2005, Dr. Flechtner developed protein and peptide-based vaccines and immunotherapies for cancer, infectious disease, autoimmunity and allergy. She is an inventor on various pending or issued patents and has multiple peer-reviewed scientific publications. Dr. Flechtner performed her post-doctoral work in the laboratory of Dr. Harvey Cantor at the Dana Farber Cancer Institute and Harvard Medical School and holds a Ph.D. in Cellular Immunology and B.S. in Animal Science from Cornell University. She is a member of the American Association of Immunologists, American Association for Cancer Research, Society for the Immunotherapy of Cancer, the President’s Council of Cornell Women, and Women in Bio.

What is the salary of Jessica Flechtner?

As the Chief Scientific Officer of Genocea Biosciences Inc, the total compensation of Jessica Flechtner at Genocea Biosciences Inc is $733,544. There are 4 executives at Genocea Biosciences Inc getting paid more, with William Clark having the highest compensation of $1,063,000.



How old is Jessica Flechtner?

Jessica Flechtner is 48, he's been the Chief Scientific Officer of Genocea Biosciences Inc since 2016. There are 13 older and 3 younger executives at Genocea Biosciences Inc. The oldest executive at Genocea Biosciences Inc is George Siber, 75, who is the Independent Director.

What's Jessica Flechtner's mailing address?

Jessica's mailing address filed with the SEC is C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE, 5TH FLOOR, CAMBRIDGE, MA, 02140.

Insiders trading at Genocea Biosciences Inc

Over the last 11 years, insiders at Genocea Biosciences Inc have traded over $9,875,933 worth of Genocea Biosciences Inc stock and bought 177,421,644 units worth $259,728,894 . The most active insiders traders include Forest Baskett, Scott D Sandell et Anthony A. Jr. Florence. On average, Genocea Biosciences Inc executives and independent directors trade stock every 27 days with the average trade being worth of $0. The most recent stock trade was executed by Diantha Duvall on 2 June 2022, trading 1,355 units of GNCA stock currently worth $81.



What does Genocea Biosciences Inc do?

Genocea's mission is to conquer cancer by developing personalized cancer immunotherapies in multiple tumor types. Our unique ATLAS™ platform comprehensively profiles each patient's T cell responses to potential targets, or antigens, on the tumor. ATLAS enables us to optimize the neoantigens for inclusion in our immunotherapies and exclude inhibitory antigens, Inhibigens™, that can exert an immunosuppressive effect. We are advancing two ATLAS-enabled programs: GEN-009, our neoantigen vaccine and GEN-011, our neoantigen-specific cell therapy using T cells derived from peripheral blood.



What does Genocea Biosciences Inc's logo look like?

Genocea Biosciences Inc logo

Complete history of Ms. Flechtner stock trades at Genocea Biosciences Inc

Date
#
Société
Initié
Trans.
Transaction
Actions Prix par action Prix ​​total Actions après Source
2 Jun 2022 Jessica Baker Flechtner
Chief Scientific Officer
Vente 1,578 $0.06 $95
2 Jun 2022
89,027
25 May 2022 Jessica Baker Flechtner
Chief Scientific Officer
Vente 16,525 $0.09 $1,487
25 May 2022
90,605
4 Apr 2022 Jessica Baker Flechtner
Chief Scientific Officer
Vente 1,212 $1.25 $1,515
4 Apr 2022
96,193
15 Mar 2022 Jessica Baker Flechtner
Chief Scientific Officer
Vente 3,349 $1.10 $3,684
15 Mar 2022
97,405
14 Dec 2015 Jessica Baker Flechtner
Chief Scientific Officer
Exercice d'option 8,906 $2.02 $17,990
14 Dec 2015
10,787
1 Sep 2015 Jessica Baker Flechtner
Chief Scientific Officer
Exercice d'option 2,229 $2.02 $4,503
1 Sep 2015
4,110
3 Aug 2015 Jessica Baker Flechtner
Chief Scientific Officer
Exercice d'option 2,229 $2.02 $4,503
3 Aug 2015
4,110
3 Aug 2015 Jessica Baker Flechtner
Chief Scientific Officer
Exercice d'option 2,229 $2.02 $4,503
3 Aug 2015
4,110
1 Jul 2015 Jessica Baker Flechtner
Chief Scientific Officer
Exercice d'option 2,229 $2.02 $4,503
1 Jul 2015
4,110
1 Jul 2015 Jessica Baker Flechtner
Chief Scientific Officer
Exercice d'option 2,229 $2.02 $4,503
1 Jul 2015
4,110
1 Jun 2015 Jessica Baker Flechtner
Chief Scientific Officer
Exercice d'option 2,229 $2.02 $4,503
1 Jun 2015
4,110
1 Jun 2015 Jessica Baker Flechtner
Chief Scientific Officer
Exercice d'option 2,229 $2.02 $4,503
1 Jun 2015
4,110
1 May 2015 Jessica Baker Flechtner
Chief Scientific Officer
Exercice d'option 2,229 $2.02 $4,503
1 May 2015
4,110
1 Apr 2015 Jessica Baker Flechtner
Chief Scientific Officer
Exercice d'option 2,283 $2.86 $6,529
1 Apr 2015
4,164
2 Mar 2015 Jessica Baker Flechtner
Chief Scientific Officer
Exercice d'option 3,754 $2.67 $10,023
2 Mar 2015
4,165
29 Jan 2015 Jessica Baker Flechtner
Chief Scientific Officer
Exercice d'option 4,699 $2.38 $11,184
29 Jan 2015
3,352
11 Sep 2014 Jessica Baker Flechtner
Chief Scientific Officer
Exercice d'option 8,115 $2.12 $17,204
11 Sep 2014
1,736


Genocea Biosciences Inc executives and stock owners

Genocea Biosciences Inc executives and other stock owners filed with the SEC include: